Daily Anesthesiology Research Analysis
Analyzed 21 papers and selected 3 impactful papers.
Summary
The three most impactful papers include a phase III randomized trial demonstrating substantial prevention of postoperative nausea and vomiting with generic aprepitant, a mechanistic study identifying microglial glutaminase 1 and ferroptosis as therapeutic targets for perioperative neurocognitive disorders, and a randomized trial showing that bundled enhanced recovery after cesarean delivery reduces perioperative adverse events. Together, these studies advance perioperative care through clinical efficacy, mechanism-based neuroprotection, and protocol-level recovery optimization.
Research Themes
- Evidence-based prevention of postoperative nausea and vomiting
- Mechanism-based prevention of perioperative neurocognitive disorders
- Enhanced recovery and multimodal perioperative care
Selected Articles
1. A multicenter parallel-group double-blind randomized placebo-controlled phase III clinical trial of generic aprepitant QLG2174 for the prevention of postoperative nausea and vomiting.
In this multicenter, double-blind, placebo-controlled phase III trial, 515 high-risk Chinese patients undergoing elective laparoscopic surgery were randomized to intravenous generic aprepitant or placebo. QLG2174 increased the 24-hour complete response rate to 70.7% versus 44.0% with placebo, an adjusted absolute difference of 26.6 percentage points, supporting clinically meaningful efficacy for postoperative nausea and vomiting prevention.
Impact: This is a comparatively large, multicenter phase III randomized trial addressing a common and patient-important anesthetic complication. The substantial absolute improvement in complete response supports potential incorporation of generic aprepitant into multimodal prophylaxis for appropriately selected high-risk patients.
Clinical Implications: Intravenous generic aprepitant administered shortly before induction may be considered as part of prophylaxis for patients with at least two risk factors for postoperative nausea and vomiting undergoing elective laparoscopic abdominal or gynecologic surgery. Local formulary, cost, safety, and combination-prophylaxis considerations remain necessary.
Key Findings
- The trial enrolled 515 patients undergoing elective laparoscopic gynecologic or abdominal surgery with at least two postoperative nausea and vomiting risk factors.
- The 24-hour complete response rate was 70.7% with QLG2174 versus 44.0% with placebo.
- The adjusted absolute treatment difference was 26.6 percentage points, with a 95% confidence interval of 18.4 to 34.7 percentage points.
Methodological Strengths
- Multicenter, parallel-group, double-blind, randomized, placebo-controlled phase III design.
- The primary endpoint of complete response incorporated both absence of vomiting and absence of rescue therapy, providing a patient-relevant composite outcome.
Limitations
- The study population was limited to Chinese patients undergoing selected elective laparoscopic procedures, which may limit generalizability.
- The provided abstract does not report the complete adverse-event profile or longer-term outcomes.
- The results address a specific QLG2174 dose and peri-induction administration strategy and may not establish superiority over all other antiemetic regimens.
Future Directions: Future trials should compare generic aprepitant directly with established neurokinin-1 receptor antagonists and multimodal prophylaxis strategies, evaluate cost-effectiveness, and assess effectiveness across diverse surgical populations and health systems.
BACKGROUND: Postoperative nausea and vomiting (PONV), a common gastrointestinal disorder following surgery, primarily occurs within 6-24 hours postoperatively, with an incidence rate of approximately 30% in general surgical patients. QLG2174 (generic aprepitant) is a neurokinin-1 (NK-1) receptor antagonist exerting antiemetic effects by blocking the binding of substance P to NK-1 receptors. This study aimed to evaluate the efficacy and safety of QLG2174 for preventing PONV in Chinese patients. MATERIALS AND METHODS: This was a multi-center, parallel-group, double-blind, randomized, placebo-controlled, phase 3 clinical trial. Patients with ≥2 PONV risk factors and scheduled for elective laparoscopic gynecologic or abdominal surgery under general anesthesia were randomized 1:1 to receive either QLG2174 32 mg or placebo via intravenous injection within 30 seconds before anesthesia induction. The primary efficacy endpoint was the proportion of patients achieving complete response (CR, defined as no vomiting and no rescue therapy use) within 24
2. Targeting microglial glutaminase 1 protects against ferroptosis-driven cognitive impairment in perioperative neurocognitive disorders.
This mechanistic study identifies ferroptosis as a key pathological process in perioperative neurocognitive disorders using a surgery- and anesthesia-induced mouse model. Pharmacological ferroptosis inhibition improved cognitive deficits, and the findings implicate microglial glutaminase 1, glutamate accumulation, and inhibition of the neuronal cystine/glutamate antiporter system Xc− as a potentially targetable pathway.
Impact: The study provides a specific molecular framework linking neuroinflammation-related glutamate dysregulation to ferroptotic neuronal injury in perioperative cognitive impairment. It offers a testable, mechanism-based therapeutic strategy rather than relying only on nonspecific perioperative prevention.
Clinical Implications: The findings support investigation of ferroptosis inhibitors or interventions targeting microglial glutaminase 1 as future preventive or therapeutic approaches for perioperative neurocognitive disorders. Clinical translation is not yet established because the evidence is preclinical.
Key Findings
- Ferroptosis was identified as a key pathological process in a surgery- and anesthesia-induced mouse model of perioperative neurocognitive disorders.
- The ferroptosis inhibitor ferrostatin-1 significantly ameliorated cognitive deficits in the mouse model.
- Brain glutamate accumulation and microglial glutaminase 1 were implicated in the pathway, potentially through competitive inhibition of neuronal system Xc−.
Methodological Strengths
- The study addresses a clinically important perioperative neurological complication using an experimentally relevant surgery- and anesthesia-induced model.
- It links a candidate molecular pathway to a pharmacological rescue phenotype, providing mechanistic and therapeutic coherence.
Limitations
- The provided abstract does not report the experimental sample size or full validation details across independent models.
- The findings are preclinical and may not translate directly to human perioperative neurocognitive disorders.
- The relative contributions of microglial glutaminase 1, glutamate accumulation, and ferroptosis require further causal dissection.
Future Directions: Future work should validate the pathway in aged and clinically diverse animal models, determine therapeutic windows and safety, and test whether biomarkers of ferroptosis or glutamatergic dysregulation identify patients who may benefit from targeted perioperative interventions.
Perioperative neurocognitive disorders (PND) are common neurological complications in elderly surgical patients, for which effective mechanism-based therapies remain lacking. This study identifies ferroptosis, an iron-dependent lipid peroxidation-driven cell death, as a key pathological process in PND, and pharmacological inhibition of ferroptosis with ferrostatin-1 significantly ameliorated cognitive deficits in a surgery and anesthesia-induced mouse model of PND. Moreover, accumulation of glutamate has been observed in the brains of PND mice, which competitively inhibits the neuronal cystine/glutamate antiporter system Xc
3. Comparison of enhanced recovery after surgery protocol and standard protocol for cesarean delivery: A two-center, double-blind, randomized controlled trial.
This two-center, double-blind randomized trial evaluated an anesthesiologist-led bundled enhanced recovery after cesarean delivery protocol in women undergoing elective cesarean delivery under spinal anesthesia. Among 116 completers, the composite perioperative adverse-event rate was 45% with ERAC versus 71% with conventional care, with an odds ratio of 0.25, indicating improved early recovery and perioperative tolerability.
Impact: The study tests a practical, bundled perioperative intervention that can be implemented across preoperative, intraoperative, and postoperative phases. Its clinically large reduction in a composite of common cesarean-related adverse events provides actionable evidence for multidisciplinary obstetric anesthesia pathways.
Clinical Implications: Anesthesiologist-led ERAC bundles incorporating vasopressor-supported hemodynamic management, multimodal non-opioid analgesia, antiemetic prophylaxis, active warming, and structured education can be considered to improve recovery after elective cesarean delivery. Local adaptation and monitoring of individual bundle components are important.
Key Findings
- A total of 122 women were randomized, and 116 completed the study: 57 received conventional care and 59 received the ERAC bundle.
- The composite perioperative adverse-event rate was 45% with ERAC versus 71% with conventional care.
- The reported odds ratio was 0.25, with a 95% confidence interval of 0.11 to 0.56; the absolute risk difference was -31.4% with a 95% confidence interval of -48.1% to -14.7%.
Methodological Strengths
- Two-center, double-blind randomized controlled design with prospectively defined composite and patient-centered recovery outcomes.
- The intervention was a clinically coherent bundle spanning education, hemodynamic management, analgesia, nausea and vomiting prophylaxis, warming, and postoperative care.
Limitations
- The sample size was modest, and the study was conducted at only two centers.
- Because multiple interventions were bundled, the independent contribution of each component cannot be determined.
- The findings concern elective cesarean delivery under spinal anesthesia and may not generalize to urgent cesarean delivery or other obstetric settings.
Future Directions: Larger pragmatic multicenter trials should evaluate ERAC implementation across diverse obstetric populations, identify the highest-value bundle components, measure maternal experience and breastfeeding-related outcomes, and assess resource use and cost-effectiveness.
BACKGROUND: Enhanced recovery after cesarean delivery (ERAC) protocols have been designed to optimize maternal recovery. Although its potential has been demonstrated, high-quality evidence supporting the efficacy of ERAC protocols remains limited. This study aimed to evaluate the effect of anesthesiologist-led bundled ERAC interventions on perioperative adverse events and recovery quality. METHODS: In this two-center, double-blind, randomized controlled trial, 122 women undergoing elective cesarean delivery under spinal anesthesia were allocated to receive either conventional care or a bundled ERAC protocol. The ERAC bundle included: preoperative personalized and information-based education; intraoperative prophylactic phenylephrine infusion, mandatory non-opioid analgesia (intravenous acetaminophen and ketorolac), prophylaxis for postoperative nausea and vomiting (ondansetron/dexamethasone), and active fluid warming; and postoperative scheduled ketorolac. The primary outcome was a composite of perioperative adverse events (hypotension, nausea/vomiting, shivering, pruritus, hypothermia, and moderate-to-severe pain). Secondary outcomes included opioid consumption, length of hospital stay, pain scores at rest and with movement, the ObsQoR-11 recovery score, and anxiety scores. RESULTS: Among 116 participants who completed the study (57 conventional care, 59 ERAC), the incidence of the primary composite outcome was significantly lower in the ERAC group (45% vs. 71%; absolute risk difference -31.4%, 95% CI -48.1% to -14.7%; odds ratio 0.25, 95% CI 0.11 to 0.56;